PARP1 and sarcopenia: Compounds that inhibit PARP1/2-mediated PARylation activity have been shown to ameliorate muscle performance/function in muscle-related diseases such as sarcopenia, Duchene muscle dystrophy, and cachexia (57–59,61,100,101).